JP5091106B2 - 真性糖尿病の治療のためのロフルミラスト - Google Patents
真性糖尿病の治療のためのロフルミラスト Download PDFInfo
- Publication number
- JP5091106B2 JP5091106B2 JP2008500172A JP2008500172A JP5091106B2 JP 5091106 B2 JP5091106 B2 JP 5091106B2 JP 2008500172 A JP2008500172 A JP 2008500172A JP 2008500172 A JP2008500172 A JP 2008500172A JP 5091106 B2 JP5091106 B2 JP 5091106B2
- Authority
- JP
- Japan
- Prior art keywords
- diabetes
- pharmaceutically acceptable
- type
- acceptable salt
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
Description
国際特許出願WO99/14239号において、真性糖尿病及び肥満の治療のための組成物が開示されている。該組成物は、活性剤A、B及びCの少なくとも2種を含有し、その際、AはcAMPの産生を刺激する少なくとも1種のホルモンであり、Bは環状ヌクレオチドの分解を阻害する少なくとも1種の物質であり、そしてCはcGMPの産生を刺激する少なくとも1種のホルモンである。国際特許出願WO01/35979号において、PDE3阻害剤とPDE4阻害剤とを肥満の治療のために組み合わせて使用することが開示されている。国際特許出願WO02/13798号において、インスリン抵抗性症候群の治療のための選択的cGMP PDE5阻害剤の使用が開示されており、そこでは、インスリン抵抗性症候群は、異脂肪症、高血圧、2型糖尿病、耐糖性障害、糖尿病の家族歴、高尿酸血症及び/又は痛風、凝血促進性状態、アテローム性動脈硬化症及び体幹の肥満から選択される2種以上の疾病状態の共存として定義される。試験がなされていないドイツ国出願DE10150517号にはテトラヒドロピリダジン−3−オン誘導体が記載されており、これはとりわけ真性糖尿病の治療のために有用かもしれない。Diabetes 47,pp.570−575,1998において、ペントキシフィリンとロリプラムが、自己免疫性糖尿病又は炎症性サイトカインの過剰産生を特徴とする他の状態に有効なことがある旨開示されている。
本発明の一つの対象は、前記の欠点の幾つか又は全てを克服した、真性糖尿病、特に2型糖尿病の治療用の医薬組成物を利用可能にすることである。
ロフルミラスト、ロフルミラスト−N−オキシド又はいずれかの製剤学的に認容性の塩は、種々の形態で投与することができる。これらの形態には、例えば液状、半固形及び固形の投与形、例えば液状溶液(例えば注入可能な溶液及び浸剤を作りうる溶液)、分散液又は懸濁液、錠剤、丸剤、粉剤、リポソーム又は坐剤が含まれる。有利な形態は、意図される投与様式と治療用途に依存する。
− インスリン及びインスリン類似体
− グルカゴン様ペプチド−1(GLP−1)受容体アゴニスト
− スルホニルウレア剤
− ビグアニド剤
− α−グルコシダーゼインヒビター
− PPAR−アゴニスト
− メグリチニド剤
− ジペプチジル−ペプチダーゼ(DPP)IVインヒビター
− PDE1、PDE5、PDE9、PDE10又はPDE11のインヒビター
− アミリンアゴニスト
− 補酵素Aインヒビター
− 抗肥満剤、例えば食欲抑制剤、満腹感増大物質及びエネルギー消費増大剤
及びそれらの製剤学的に認容性の塩。
式1.1の化合物もしくはその製剤学的に認容性の塩及び/又は式1.2の化合物もしくはその製剤学的に認容性の塩の量と、2型糖尿病及び/又は1型糖尿病の治療において使用される他の1種以上の有効化合物もしくはその製剤学的に認容性の塩の量とを含有し、その際、第一の量と第二の量とが一緒になって、2型糖尿病及び/又は1型糖尿病の治療のために有効な量をなす組成物;並びに2型糖尿病及び/又は1型糖尿病の治療において使用するための前記の組成物。
成分:(A)式1.1の化合物もしくはその製剤学的に認容性の塩及び/又は式1.2の化合物もしくはその製剤学的に認容性の塩の量と、(B)2型糖尿病及び/又は1型糖尿病の治療において使用される他の1種の有効化合物もしくはその製剤学的に認容性の塩の量と、場合により(C)2型糖尿病及び/又は1型糖尿病の治療において使用される更にもう一つの有効化合物もしくはその製剤学的に認容性の塩の量とを含有し、その際、第一の量と、第二の量と、場合により存在する第三の量とが一緒になって、2型糖尿病及び/又は1型糖尿病の治療に有効な量をなし、かつ成分(A)と(B)と(C)のそれぞれが、少なくとも1種の製剤学的に認容性の助剤と混合して製剤化されている組み合わせ製品。
− インスリン及びインスリン類似体
− グルカゴン様ペプチド−1(GLP−1)受容体アゴニスト
− スルホニルウレア剤
− ビグアニド剤
− α−グルコシダーゼインヒビター
− PPAR−アゴニスト
− メグリチニド剤
− ジペプチジル−ペプチダーゼ(DPP)IVインヒビター
− PDE1、PDE5、PDE9、PDE10又はPDE11のインヒビター
− アミリンアゴニスト
− 補酵素Aインヒビター
− 抗肥満剤、例えば食欲抑制剤、満腹感増大物質及びエネルギー消費増大剤
及びそれらの製剤学的に認容性の塩
からなる群から選択される。
− インスリン及びインスリン類似体
− グルカゴン様ペプチド−1(GLP−1)受容体アゴニスト
− スルホニルウレア剤
− ビグアニド剤
− α−グルコシダーゼインヒビター
− PPAR−アゴニスト
− メグリチニド剤
− ジペプチジル−ペプチダーゼ(DPP)IVインヒビター
− PDE1、PDE5、PDE9、PDE10又はPDE11のインヒビター
− アミリンアゴニスト
− 補酵素Aインヒビター
− 抗肥満剤、例えば食欲抑制剤、満腹感増大物質及びエネルギー消費増大剤
及びそれらの製剤学的に認容性の塩
からなる群から選択される。
本発明による組合せ物は、任意の好適な経路によって、例えば経口、舌下、頬内、静脈内、動脈内、筋内、皮下、皮内、局所、経皮、鼻内、腹腔内、直腸内又は膣内の投与によって、吸入又は吹込によって投与することができる。
製剤学的に認容性の助剤として、医薬組成物(製剤)の製造に適していることが知られる任意の助剤を使用することができる。その例は、これらに制限されないが、溶剤、賦形剤、分散剤、乳化剤、溶解剤、ゲル形成剤、軟膏基剤、酸化防止剤、保存剤、安定剤、担体、充填剤、結合剤、増粘剤、錯形成剤、崩壊剤、緩衝剤、透過促進剤、ポリマー、滑沢剤、被覆剤、噴射剤、浸透圧調整剤、界面活性剤、着色剤、フレーバー、甘味料及び色素を含む。特に、所望の配合及び所望の投与様式に適した型の助剤が使用される。
モデル
M&B A/S(8680 Ry,デンマーク)から入手した10〜11週齢の雌のC57BLKS db/dbマウスを試験で使用した。マウスを1ケージあたり10匹入れて、水と齧歯類に標準的な研究用飼料(chow 3433,Provimi Kliba SA,4303 Kaiseraugst、スイス在)に自由に到達できるようにした。
マウスを偏狭な動物実験施設に1週間なじませ、眼窩後方の血液試料を試験開始の3〜7日前に得た。
第6表は、ロフルミラスト−N−オキシドの投与前とその間でのその日のマウスの水分摂取量(24時間間隔)を示している:
第6表:
第3表は、グルコース適用15分後の血中グルコースレベルを示している。マウスを、10日間ロフルミラストで処理した。
ロフルミラスト−N−オキシドでの処理は、用量依存的に、db/dbマウスの一日摂食量を減少させることが裏付けられた。更に、高い血中グルコースレベルの結果である糖尿により高められたdb/dbマウスの一日水分摂取量は、ロフルミラスト−N−オキシドでの処理の間に低減された。更に、ロフルミラスト又はロフルミラスト−N−オキシドでの処理は、前記に詳説した生化学的試験によればdb/dbマウスにおいて空腹時と食後の血中グルコースレベルを下げることが裏付けられた。
Claims (5)
- ロフルミラストもしくはその製剤学的に認容性の塩及び/又はロフルミラスト−N−オキシドもしくはその製剤学的に認容性の塩を、2型糖尿病の治療用の医薬組成物の製造のために用いる使用。
- ロフルミラスト又はその製剤学的に認容性の塩を、2型糖尿病の治療のための医薬組成物の製造のために用いる使用。
- ロフルミラスト−N−オキシド又はその製剤学的に認容性の塩を、2型糖尿病の治療のための医薬組成物の製造のために用いる使用。
- ロフルミラスト又はその製剤学的に認容性の塩を、単独療法剤として、2型糖尿病の治療のための医薬組成物の製造のために用いる使用。
- ロフルミラスト−N−オキシド又はその製剤学的に認容性の塩を、単独療法剤として、2型糖尿病の治療のための医薬組成物の製造のために用いる使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05101772.1 | 2005-03-08 | ||
EP05101772 | 2005-03-08 | ||
PCT/EP2006/060418 WO2006094933A1 (en) | 2005-03-08 | 2006-03-03 | Roflumilast for the treatment of diabetes mellitus |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012129982A Division JP5611275B2 (ja) | 2005-03-08 | 2012-06-07 | 真性糖尿病の治療のためのロフルミラスト |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2008532974A JP2008532974A (ja) | 2008-08-21 |
JP2008532974A5 JP2008532974A5 (ja) | 2009-04-30 |
JP5091106B2 true JP5091106B2 (ja) | 2012-12-05 |
Family
ID=34938922
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008500172A Expired - Fee Related JP5091106B2 (ja) | 2005-03-08 | 2006-03-03 | 真性糖尿病の治療のためのロフルミラスト |
JP2012129982A Expired - Fee Related JP5611275B2 (ja) | 2005-03-08 | 2012-06-07 | 真性糖尿病の治療のためのロフルミラスト |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012129982A Expired - Fee Related JP5611275B2 (ja) | 2005-03-08 | 2012-06-07 | 真性糖尿病の治療のためのロフルミラスト |
Country Status (16)
Country | Link |
---|---|
US (2) | US8017633B2 (ja) |
EP (1) | EP1874308A1 (ja) |
JP (2) | JP5091106B2 (ja) |
KR (1) | KR101302838B1 (ja) |
CN (2) | CN102600144A (ja) |
AU (1) | AU2006222060B2 (ja) |
BR (1) | BRPI0609371A2 (ja) |
CA (1) | CA2599376C (ja) |
EA (1) | EA015382B1 (ja) |
HK (1) | HK1116077A1 (ja) |
IL (2) | IL185277A (ja) |
MX (1) | MX2007010560A (ja) |
NO (1) | NO20074943L (ja) |
NZ (1) | NZ560269A (ja) |
WO (1) | WO2006094933A1 (ja) |
ZA (1) | ZA200706294B (ja) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3993169B2 (ja) | 2002-02-11 | 2007-10-17 | アンタレス・ファーマ・インコーポレーテッド | 皮内注射器 |
FI1850892T4 (fi) | 2005-01-24 | 2023-08-31 | Neula-avusteinen esitäytetyn ruiskun omaava suihkuinjektori | |
NZ560269A (en) * | 2005-03-08 | 2010-12-24 | Nycomed Gmbh | Roflumilast for the treatment of diabetes mellitus |
TW200738266A (en) * | 2005-09-29 | 2007-10-16 | Sankyo Co | Pharmaceutical agent containing insulin resistance improving agent |
US9144648B2 (en) | 2006-05-03 | 2015-09-29 | Antares Pharma, Inc. | Injector with adjustable dosing |
WO2007131013A1 (en) | 2006-05-03 | 2007-11-15 | Antares Pharma, Inc. | Two-stage reconstituting injector |
EP2213289A1 (en) * | 2006-09-07 | 2010-08-04 | Nycomed GmbH | Combination treatment for diabetes mellitus |
EP2268342B1 (en) | 2008-03-10 | 2015-09-16 | Antares Pharma, Inc. | Injector safety device |
CN101548972B (zh) * | 2008-04-03 | 2012-10-17 | 万特制药(海南)有限公司 | 一种含有瑞格列奈的固体药物组合物 |
EP3581224A1 (en) | 2008-08-05 | 2019-12-18 | Antares Pharma, Inc. | Multiple dosage injector |
JP5732039B2 (ja) | 2009-03-20 | 2015-06-10 | アンタレス・ファーマ・インコーポレーテッド | 危険有害性薬剤の注入システム |
US9220660B2 (en) | 2011-07-15 | 2015-12-29 | Antares Pharma, Inc. | Liquid-transfer adapter beveled spike |
US8496619B2 (en) | 2011-07-15 | 2013-07-30 | Antares Pharma, Inc. | Injection device with cammed ram assembly |
US20130172303A1 (en) * | 2012-01-03 | 2013-07-04 | Forest Laboratories Holdings Ltd. | Roflumilast compositions for the treatment of copd |
DK2822618T3 (da) | 2012-03-06 | 2024-01-22 | Antares Pharma Inc | Forfyldt nål med brudkraftfunktion |
AU2013203784A1 (en) | 2012-04-06 | 2013-10-24 | Kaushik J. Dave | Needle assisted jet injection administration of testosterone compositions |
US9364610B2 (en) | 2012-05-07 | 2016-06-14 | Antares Pharma, Inc. | Injection device with cammed ram assembly |
WO2014124464A1 (en) | 2013-02-11 | 2014-08-14 | Travanty Michael | Needle assisted jet injection device having reduced trigger force |
WO2014124860A1 (en) | 2013-02-14 | 2014-08-21 | Boehringer Ingelheim International Gmbh | Specific pde4b-inhibitors for the treatment of diabetes mellitus |
US9707354B2 (en) | 2013-03-11 | 2017-07-18 | Antares Pharma, Inc. | Multiple dosage injector with rack and pinion dosage system |
WO2014165136A1 (en) | 2013-03-12 | 2014-10-09 | Antares Pharma, Inc. | Constant volume prefilled syringes and kits thereof |
EP3165224A1 (en) * | 2015-11-09 | 2017-05-10 | Albert-Ludwigs-Universität Freiburg | Use of pde4 inhibitors for the prophylaxis and/or therapy of dyslipoproteinaemia and related disorders |
AU2017252015A1 (en) | 2016-04-19 | 2018-11-08 | Ureka Sarl | Peptide-oligourea foldamer compounds and methods of their use |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3174901A (en) * | 1963-01-31 | 1965-03-23 | Jan Marcel Didier Aron Samuel | Process for the oral treatment of diabetes |
JPS5869812A (ja) | 1981-10-22 | 1983-04-26 | Chugai Pharmaceut Co Ltd | 血糖降下剤 |
AR240698A1 (es) * | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
NZ225447A (en) | 1987-07-20 | 1991-12-23 | Merck & Co Inc | Piperazinyl derivatives of purine and purine isosteres and pharmaceutical compositions |
US5698711A (en) * | 1991-01-28 | 1997-12-16 | Rhone-Poulenc Rorer Limited | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group |
GB9215633D0 (en) | 1992-07-23 | 1992-09-09 | Smithkline Beecham Plc | Novel treatment |
WO1994002465A1 (en) | 1992-07-28 | 1994-02-03 | Rhone-Poulenc Rorer Limited | INHIBITORS OF c-AMP PHOSPHODIESTERASE AND TNF |
EP0671936A1 (en) * | 1992-10-15 | 1995-09-20 | Dana-Farber Cancer Institute, Inc. | TREATMENT OF INSULIN RESISTANCE IN OBESITY LINKED TYPE II DIABETES USING ANTAGONISTS TO TNF-$g(a) FUNCTION |
JP3093271B2 (ja) * | 1993-07-02 | 2000-10-03 | ビイク グルデン ロンベルク ヒェーミッシェ ファブリーク ゲゼルシャフト ミット ベシュレンクテル ハフツング | フルオルアルコキシ置換のベンズアミド及び環状ヌクレオチドホスホジエステラーゼ阻害剤としてのその使用 |
HUT76980A (hu) * | 1994-08-29 | 1998-01-28 | Yamanouchi Pharmaceutical Co. Ltd. | Új naftiridinszármazékok és ezeket a vegyületeket tartalmazó gyógyászati készítmények |
KR100454781B1 (ko) * | 1996-01-31 | 2005-04-08 | 알타나 파마 아게 | 신규한페난트리딘 |
DE19617864A1 (de) * | 1996-04-23 | 1997-10-30 | Schering Ag | Neue chirale Phenyldihydrofuranone |
US6331543B1 (en) * | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
DE59811840D1 (de) * | 1997-09-12 | 2004-09-23 | Pharis Biotec Gmbh | Zusammensetzung zur therapie von diabetes mellitus und fettsucht |
SE9801992D0 (sv) * | 1998-06-04 | 1998-06-04 | Astra Ab | New 3-aryl-2-hydroxypropionic acid derivative I |
ATE294793T1 (de) | 1999-01-15 | 2005-05-15 | Altana Pharma Ag | Phenantrhridin-n-oxides mit pde-iv hemmender wirkung |
NZ512872A (en) | 1999-01-15 | 2003-07-25 | Altana Pharma Ag | Phenylphenanthridines with PDE-IV inhibiting activity |
US7323496B2 (en) * | 1999-11-08 | 2008-01-29 | Theracos, Inc. | Compounds for treatment of inflammation, diabetes and related disorders |
WO2001035979A2 (en) | 1999-11-13 | 2001-05-25 | Icos Corporation | Combined pde3 and pde4 inhibitor therapy for the treatment of obesity |
WO2001042244A1 (fr) | 1999-12-08 | 2001-06-14 | Grelan Pharmaceutical Co., Ltd. | Nouveaux derives 1,8-naphtyridin-2(1h)-one |
US6423714B2 (en) * | 2000-03-13 | 2002-07-23 | Ortho Mcneil-Pharmaceutical, Inc.. | Cyclohexene derivatives useful as antagonists of the motilin receptor |
CA2404226A1 (en) * | 2000-03-23 | 2001-09-27 | Takeda Chemical Industries, Ltd. | Furoisoquinoline derivatives, process for producing the same and use thereof |
JP2003534328A (ja) * | 2000-05-25 | 2003-11-18 | メルク フロスト カナダ アンド カンパニー | フルオロアルコキシ置換ベンズアミドジクロロピリジニルn−オキシドpde4阻害剤 |
IL154231A0 (en) * | 2000-08-11 | 2003-07-31 | Ono Pharmaceutical Co | Piperidine derivatives and drugs containing these derivatives as the active ingredient |
KR20030023747A (ko) | 2000-08-11 | 2003-03-19 | 화이자 인코포레이티드 | 인슐린 저항성 증후군의 치료 |
CN100378075C (zh) | 2001-01-22 | 2008-04-02 | 记忆药物公司 | 用作磷酸二酯酶4抑制剂的苯胺衍生物 |
EE200300362A (et) * | 2001-01-31 | 2003-12-15 | Pfizer Products Inc. | PDE4 isosüümide inhibiitoritena kasutatavad tiasolüül-, oksasolüül-, pürrolüül- ja imidasolüülhappeamiidi derivaadid |
HUP0302891A2 (hu) * | 2001-01-31 | 2003-12-29 | Pfizer Products Inc. | PDE4 izoenzimek inhibitoraiként alkalmazható éterszármazékok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények |
WO2002064584A1 (en) | 2001-02-15 | 2002-08-22 | Altana Pharma Ag | Phthalayinone-piperidino-derivatives as pde4 inhibitors |
EP1370211A4 (en) * | 2001-03-02 | 2005-02-09 | Bristol Myers Squibb Co | SIMULTANEOUS ADMINISTRATION OF MELANOCORTIN RECEPTOR AGONISTS AND A PHOSPHODIESTERASE HEMMER FOR THE TREATMENT OF DISEASES RELATED TO CYCLIC AMP |
UA74912C2 (en) * | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
DE10150517A1 (de) | 2001-10-12 | 2003-04-17 | Merck Patent Gmbh | Verwendung von Phosphodiesterase IV-Inhibitoren |
US20030181461A1 (en) | 2002-01-25 | 2003-09-25 | Lautt Wilfred Wayne | Use of phosphodiesterase antagonists to treat insulin resistance |
PL397021A1 (pl) * | 2002-05-28 | 2012-03-26 | Nycomed Gmbh | Preparat farmaceutyczny do podawania miejscowego |
AU2003253130A1 (en) * | 2002-08-19 | 2004-03-03 | Glenmark Pharmaceuticals Limited | Condensed heterocyclic compounds as pde-iv inhibitors for the treatment of inflammatory and allergic disorders |
WO2004067006A1 (en) * | 2003-01-27 | 2004-08-12 | Pharmacia Corporation | Combination of a pde iv inhibitor and a tnf-alpha antagonist |
WO2004098595A1 (en) | 2003-05-12 | 2004-11-18 | Altana Pharma Ag | COMPOSITION COMPRISING ROFLUMILAST AND A TNFα ANTAGONIST |
WO2004098598A1 (en) | 2003-05-12 | 2004-11-18 | Altana Pharma Ag | COMPOSITION COMPRISING ROFLUMILAST AND A TNFα ANTAGONIST |
WO2004098596A1 (en) | 2003-05-12 | 2004-11-18 | Altana Pharma Ag | Composition comprising roflumilast and il-1 trap |
WO2004098597A1 (en) | 2003-05-12 | 2004-11-18 | Altana Pharma Ag | Composition comprising roflumilast and shuil-1r ii |
MXPA05012302A (es) * | 2003-05-22 | 2006-01-30 | Altana Pharma Ag | Composicion que comprende un inhibidor de pde4 y un inhibidor de pde5. |
WO2005020926A2 (en) | 2003-08-28 | 2005-03-10 | Pharmacia Corporation | Treatment or prevention of vascular disorders with cox-2 inhibitors in combination with cyclic amp-specific phosphodiesterase inhibitors |
AU2004269923B2 (en) * | 2003-09-05 | 2010-05-13 | Takeda Gmbh | Use of PDE4 inhibitors for the treatment of diabetes mellitus |
BRPI0415753A (pt) | 2003-10-21 | 2006-12-19 | Pharmacia Corp | método para tratamento e prevenção da inflamação respiratória com um inibidor de ciclooxigenase-2 em associação com um inibidor de fosfodiesterase 4 e composições que os contêm |
WO2005116653A2 (en) | 2004-04-13 | 2005-12-08 | Arena Pharmaceuticals, Inc. | Modulators of human g protein-coupled receptors for the treatment of hyperglycemia and related disorders |
NZ560269A (en) * | 2005-03-08 | 2010-12-24 | Nycomed Gmbh | Roflumilast for the treatment of diabetes mellitus |
-
2006
- 2006-03-03 NZ NZ560269A patent/NZ560269A/en not_active IP Right Cessation
- 2006-03-03 CN CN2012100579547A patent/CN102600144A/zh active Pending
- 2006-03-03 KR KR1020077022434A patent/KR101302838B1/ko not_active IP Right Cessation
- 2006-03-03 US US11/885,450 patent/US8017633B2/en not_active Expired - Fee Related
- 2006-03-03 JP JP2008500172A patent/JP5091106B2/ja not_active Expired - Fee Related
- 2006-03-03 AU AU2006222060A patent/AU2006222060B2/en not_active Ceased
- 2006-03-03 EA EA200701845A patent/EA015382B1/ru not_active IP Right Cessation
- 2006-03-03 CN CN2006800072465A patent/CN101137368B/zh not_active Expired - Fee Related
- 2006-03-03 MX MX2007010560A patent/MX2007010560A/es not_active Application Discontinuation
- 2006-03-03 CA CA2599376A patent/CA2599376C/en not_active Expired - Fee Related
- 2006-03-03 BR BRPI0609371-0A patent/BRPI0609371A2/pt not_active IP Right Cessation
- 2006-03-03 WO PCT/EP2006/060418 patent/WO2006094933A1/en active Application Filing
- 2006-03-03 EP EP06708617A patent/EP1874308A1/en not_active Withdrawn
-
2007
- 2007-07-27 ZA ZA200706294A patent/ZA200706294B/xx unknown
- 2007-08-14 IL IL185277A patent/IL185277A/en not_active IP Right Cessation
- 2007-10-01 NO NO20074943A patent/NO20074943L/no not_active Application Discontinuation
-
2008
- 2008-06-11 HK HK08106441.4A patent/HK1116077A1/xx not_active IP Right Cessation
-
2011
- 2011-07-11 US US13/179,895 patent/US8541456B2/en not_active Expired - Fee Related
-
2012
- 2012-06-07 JP JP2012129982A patent/JP5611275B2/ja not_active Expired - Fee Related
- 2012-07-18 IL IL221006A patent/IL221006A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20080214625A1 (en) | 2008-09-04 |
HK1116077A1 (en) | 2008-12-19 |
CA2599376C (en) | 2014-05-13 |
AU2006222060B2 (en) | 2011-09-01 |
US8017633B2 (en) | 2011-09-13 |
AU2006222060A1 (en) | 2006-09-14 |
MX2007010560A (es) | 2008-02-21 |
IL185277A (en) | 2013-08-29 |
EA015382B1 (ru) | 2011-08-30 |
NZ560269A (en) | 2010-12-24 |
KR101302838B1 (ko) | 2013-09-03 |
BRPI0609371A2 (pt) | 2010-03-30 |
JP2008532974A (ja) | 2008-08-21 |
KR20070111539A (ko) | 2007-11-21 |
NO20074943L (no) | 2007-10-01 |
US20110269750A1 (en) | 2011-11-03 |
US8541456B2 (en) | 2013-09-24 |
JP5611275B2 (ja) | 2014-10-22 |
CN102600144A (zh) | 2012-07-25 |
IL185277A0 (en) | 2008-02-09 |
WO2006094933A1 (en) | 2006-09-14 |
IL221006A0 (en) | 2012-08-30 |
JP2012188448A (ja) | 2012-10-04 |
EP1874308A1 (en) | 2008-01-09 |
EA200701845A1 (ru) | 2008-02-28 |
CA2599376A1 (en) | 2006-09-14 |
CN101137368A (zh) | 2008-03-05 |
CN101137368B (zh) | 2012-05-16 |
ZA200706294B (en) | 2008-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5091106B2 (ja) | 真性糖尿病の治療のためのロフルミラスト | |
JP2010502670A (ja) | 真性糖尿病のための組合せ治療 | |
JP6066144B2 (ja) | 併用医薬 | |
JP2019108392A (ja) | DPP−4阻害薬とα−グルコシダーゼ阻害薬との組合せ | |
KR102371364B1 (ko) | 당뇨병 치료를 위한 글루코키나아제 활성화제 조성물 | |
JP2002529417A (ja) | スルホニル尿素、グリタゾンおよびビグアニドを含有する糖尿病用組み合わせ薬剤 | |
JP2008509145A (ja) | 抗糖尿病性経口インスリン−ビグアニドの組み合わせ | |
WO2013174767A1 (en) | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference | |
TW202317109A (zh) | 控制血糖值之方法及糖尿病與相關病症之治療 | |
WO2006094942A1 (en) | Roflumilast for the treatment of diabetes mellitus | |
NL8502178A (nl) | Nieuwe farmaceutische preparaten. | |
BRPI0920699A2 (pt) | uso de um inibidor de dpp-4 no tratamento de diabetes em pacientes com controle insuficiente da glicemia apesar de terapia com um fármaco antidiabético oral ou não-oral | |
AU2011253752A1 (en) | Roflumilast for the treatment of diabetes mellitus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090302 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090302 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20101228 Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20101227 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120307 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120607 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120822 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120913 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150921 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150921 Year of fee payment: 3 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
LAPS | Cancellation because of no payment of annual fees |